Shoback DG, Gardner D, eds. Chapter 17. Greenspan’s basic & clinical endocrinology (9th ed.). 2011. New York: McGraw-Hill Medical. ISBN 978–0–07–162243–1.
Sunkara Gangadhar, Sabo Ron, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, healthy volunteers. J Clin Pharmacol. 2007;47:1152–8.
He Y-L, Sadler BM, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46(9):787–802.
He Handan, Tran Phi, et al. Absorption, metabolism, and excretion of [14C] vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metabolism and Disposition. 2009;37(3):536–44.
The use of physiologically based pharmacokinetic analyses – biopharmaceutics applications for oral drug product development, manufacturing changes, and controls. Guidance for Industry. Draft Guidance. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), October 2020
Guideline on reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA), December 2018.
Extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations. Guidance for Industry; U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), September 1997
Al-Tabakha Moawia M, Alomer Muaed J. In vitro dissolution and in silico modeling shortcuts in bioequivalence testing. Pharmaceutics. 2020;12:45.
McAllister M, Flanagan T, Boon K, et al. Developing relevant dissolution specifications for oral drug products - industrial and regulatory perspectives. Pharmaceutics. 2019;12(1):19.
Sjögren E, Thörn H, Tannergren C. In silico modeling of gastrointestinal drug absorption: predictive performance of three physiologically based absorption models. Mol Pharmaceutics. 2016;13:1763–78.
May Almukainzi, Arthur Okumu, Hai Wei and Raimar Löbenberg. Simulation of in vitro dissolution behavior using DDDPlus™. AAPS PharmSciTech, Vol. 16, No. 1, February 2015
GastroPlus™ User Manual for Version 9.7. Lancaster, CA: Simulations Plus, 2019
DDDPlus® User Manual for Version 6.0. Lancaster, CA: Simulations Plus, 2018
McAllister M, Flanagan T, Boon K, Pepin X, Tistaert C, Jamei M, Abend A, Kotzagiorgis E, Mackie C. Developing clinically relevant dissolution specifications for oral drug products - industrial and regulatory perspectives. Pharmaceutics. 2020;12:19.
Food and Drug Administration. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation and Application of In Vitro/In Vivo Correlations. 1997.
European Medicines Agency. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms. 2014
DR Mould; RN Upton; Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development; Pharmacometrics & Systems Pharmacology (2012) 1, e6.
Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass Index/body fat percent relationship. Obes Rev. 2002;3(3):141–6.
Zhang X, Lionberger RA, Davit BM, Yu LX. Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J. 2011;13:59–71.
Miller NA, Graves RH, Edwards CD, et al. Physiologically based pharmacokinetic modelling of inhaled nemiralisib: mechanistic components for pulmonary absorption, systemic distribution, and oral absorption. Clin Pharmacokinet. 2021.
Yang F, et al. Prediction of a therapeutic dose for buagafuran, a potent anxiolytic agent by physiologically based pharmacokinetic/pharmacodynamic modeling starting from pharmacokinetics in rats and human. Front Pharmacol. 2017;8:683.
Basu S, et al. Physiologically based pharmacokinetic modeling to evaluate formulation factors influencing bioequivalence of metoprolol extended-release products. J Clin Pharmacol. 2019;59(9):1252–63.
Babiskin A, Zhang X. Application of physiologically based absorption modeling for amphetamine salts drug products in generic drug evaluation. J Pharm Sci. 2015;104:3710–3180.